Latham Advises on Viking Therapeutics’ Upsized US$500 Million Offering of Common Stock and Convertible Senior Notes
Viking Therapeutics (VKTX) priced a US$500M offering, including 7.86M shares at US$35 each and US$225M in convertible notes. Underwriters have options to buy more. Latham & Watkins advised the underwriters. The offerings are set to close September 25, 2026, subject to conditions.
How this was made
The 30-second read
Why it matters
The $500M equity raise and $225M convertible notes provide substantial funding for R&D, but introduce dilution and future debt conversion risk.
Market read
Primary disclosure of a large capital raise; traders can act on pricing and settlement details.
What to watch
Potential dilution from the underwriters' option and future convertible note conversions could pressure the stock.
Background
Viking Therapeutics is a clinical‑stage biotech focused on metabolic and endocrine disorders.
Ticker impact
Viking Therapeutics priced a $500M common stock offering and $225M convertible notes, first public disclosure of the raise.
Potential short-term upside on news, followed by dilution pressure.
Large raise at $35 per share indicates strong investor demand; convertible notes add debt but low coupon.
Market effects
May boost sentiment for biotech financing and set a pricing benchmark for similar-stage companies.
Limited to US biotech investors; no broader regional effect.
Modest, as the raise is company-specific without macro implications.
Counterpoint
The high price may overvalue the company's pipeline, leading to a post‑offering price correction.
Key entities
- law firmLatham & Watkins LLP
Legal advisor to the underwriters.
